Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NPCE

NPCE - NeuroPace, Inc. Stock Price, Fair Value and News

$14.10-0.02 (-0.14%)
Market Closed

35/100

NPCE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

35/100

NPCE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

NPCE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NPCE Price Action

Last 7 days

0.5%

Last 30 days

-3.2%

Last 90 days

-12.9%

Trailing 12 Months

35.2%

NPCE RSI Chart

NPCE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NPCE Valuation

Market Cap

474.7M

Price/Earnings (Trailing)

-22.12

Price/Sales (Trailing)

4.75

Price/Free Cashflow

-41.87

NPCE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

NPCE Fundamentals

NPCE Revenue

Revenue (TTM)

100.0M

Rev. Growth (Yr)

23.86%

Rev. Growth (Qtr)

-2.8%

NPCE Earnings

Earnings (TTM)

-21.5M

Earnings Growth (Yr)

48.02%

Earnings Growth (Qtr)

21.94%

NPCE Profitability

Return on Equity

-112.79%

Return on Assets

-20.33%

Free Cashflow Yield

-2.39%

NPCE Investor Care

Shares Dilution (1Y)

3.40%

Diluted EPS (TTM)

-0.66

NPCE Alerts

  • 1 major insider sales recently.
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202584.3M88.6M94.9M100.0M
202469.1M71.8M76.5M79.9M
202348.6M54.9M60.2M65.4M
202245.3M42.9M43.7M45.5M
202142.4M47.4M44.9M45.2M
202000041.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About NeuroPace, Inc.

NPCE
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
 CEO
 WEBSITEneuropace.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES169

NeuroPace, Inc. Frequently Asked Questions

NPCE is the stock ticker symbol of NeuroPace, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of NeuroPace, Inc. is 474.7 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, NPCE's PE ratio (Price to Earnings) is -22.12 and Price to Sales (PS) ratio is 4.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NPCE PE ratio will change depending on the future growth rate expectations of investors.